National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Clin Immunol. 2010 Jul;136(1):42-50. doi: 10.1016/j.clim.2010.02.010. Epub 2010 Mar 15.
Biomarkers could be useful in evaluating immune reconstitution inflammatory syndrome (IRIS). A cohort of 45 HIV-1-infected, antiretroviral treatment (ART)-naive patients with baseline CD4 T cell counts <or=100 cells/microL who were started on ART, suppressed HIV-RNA to <50 copies/mL, and seen every 1-3 months for 1 year were retrospectively evaluated for suspected or confirmed IRIS. d-Dimer, C-reactive protein (CRP), and selected autoantibodies were analyzed at baseline, 1 and 3 months post-ART in cryopreserved plasma. Median differences between cases and controls were compared with Mann-Whitney and Fisher's exact tests. Sixteen patients (35.6%) developed IRIS (median of 35 days post-ART initiation): unmasking=8, paradoxical=7, autoimmune=1. Pre-ART d-dimer and CRP were higher in IRIS cases versus controls (d-dimer: 0.89 mg/L versus 0.66 mg /L, p=0.037; CRP: 0.74 mg/L versus 0.39 mg/L, p=0.022), while d-dimer was higher in unmasking cases at IRIS onset (2.04 mg/L versus 0.36 mg /L, p=0.05). These biomarkers may be useful in identifying patients at risk for IRIS.
生物标志物可用于评估免疫重建炎症综合征 (IRIS)。本研究回顾性分析了 45 例基线 CD4 T 细胞计数<或=100 个/μL 的 HIV-1 感染、未接受过抗逆转录病毒治疗 (ART) 的初治患者,这些患者接受 ART 治疗后 HIV-RNA 被抑制至<50 拷贝/mL,并且在 1 年内每 1-3 个月随访 1 次。这些患者疑似或确诊为 IRIS。在冷冻保存的血浆中,分别于基线、ART 后 1 个月和 3 个月检测 d-二聚体、C 反应蛋白 (CRP) 和选定的自身抗体。采用 Mann-Whitney 和 Fisher 确切概率法比较病例组和对照组的中位数差异。16 例患者(35.6%)发生 IRIS(ART 治疗后中位 35 天):脱靶=8 例,矛盾=7 例,自身免疫=1 例。IRIS 组患者的 d-二聚体和 CRP 在 ART 前高于对照组(d-二聚体:0.89 mg/L 与 0.66 mg/L,p=0.037;CRP:0.74 mg/L 与 0.39 mg/L,p=0.022),而在脱靶型 IRIS 患者中,d-二聚体在 IRIS 发病时更高(2.04 mg/L 与 0.36 mg/L,p=0.05)。这些生物标志物可能有助于识别发生 IRIS 的风险患者。